Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial
Authors
Keywords
-
Journal
LANCET
Volume 399, Issue 10336, Pages 1718-1729
Publisher
Elsevier BV
Online
2022-04-01
DOI
10.1016/s0140-6736(22)00562-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): distant metastasis-free survival results from a double-blind, randomised, controlled, phase 3 trial
- (2021) Alexander M M Eggermont et al. LANCET ONCOLOGY
- Adjuvant pembrolizumab versus placebo in resected stage III melanoma (EORTC 1325-MG/KEYNOTE-054): health-related quality-of-life results from a double-blind, randomised, controlled, phase 3 trial
- (2021) Andrew Bottomley et al. LANCET ONCOLOGY
- Prognosis of Patients With Stage III Melanoma According to American Joint Committee on Cancer Version 8: A Reassessment on the Basis of 3 Independent Stage III Melanoma Cohorts
- (2020) Claus Garbe et al. JOURNAL OF CLINICAL ONCOLOGY
- Longer Follow-Up Confirms Recurrence-Free Survival Benefit of Adjuvant Pembrolizumab in High-Risk Stage III Melanoma: Updated Results From the EORTC 1325-MG/KEYNOTE-054 Trial
- (2020) Alexander M. M. Eggermont et al. JOURNAL OF CLINICAL ONCOLOGY
- Preferences for Immunotherapy in Melanoma: A Systematic Review
- (2019) Ann Livingstone et al. ANNALS OF SURGICAL ONCOLOGY
- Considering adjuvant therapy for stage II melanoma
- (2019) Andrew S. Poklepovic et al. CANCER
- Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma
- (2018) Alexander M.M. Eggermont et al. NEW ENGLAND JOURNAL OF MEDICINE
- Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II–III Melanoma Adjuvant Therapy
- (2017) Stefan Suciu et al. JNCI-Journal of the National Cancer Institute
- Targeted agents and immunotherapies: optimizing outcomes in melanoma
- (2017) Jason J. Luke et al. Nature Reviews Clinical Oncology
- Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma
- (2017) Jeffrey Weber et al. NEW ENGLAND JOURNAL OF MEDICINE
- Adjuvant Dabrafenib plus Trametinib in Stage III BRAF-Mutated Melanoma
- (2017) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Relapse-Free Survival as a Surrogate for Overall Survival in the Evaluation of Stage II–III Melanoma Adjuvant Therapy
- (2017) Stefan Suciu et al. JNCI-Journal of the National Cancer Institute
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started